Stifel Financial Corp Trims Stake in Valeant Pharmaceuticals Intl Inc (VRX)

Stifel Financial Corp lessened its holdings in shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) by 3.0% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 211,522 shares of the specialty pharmaceutical company’s stock after selling 6,601 shares during the quarter. Stifel Financial Corp owned about 0.06% of Valeant Pharmaceuticals Intl worth $3,360,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Bank of New York Mellon Corp lifted its position in shares of Valeant Pharmaceuticals Intl by 2.2% during the fourth quarter. Bank of New York Mellon Corp now owns 359,894 shares of the specialty pharmaceutical company’s stock worth $7,479,000 after purchasing an additional 7,683 shares in the last quarter. Mackenzie Financial Corp lifted its position in shares of Valeant Pharmaceuticals Intl by 339.6% during the fourth quarter. Mackenzie Financial Corp now owns 568,781 shares of the specialty pharmaceutical company’s stock worth $11,819,000 after purchasing an additional 439,383 shares in the last quarter. Bogle Investment Management L P DE acquired a new stake in shares of Valeant Pharmaceuticals Intl during the fourth quarter worth about $14,256,000. Spark Investment Management LLC acquired a new stake in shares of Valeant Pharmaceuticals Intl during the fourth quarter worth about $812,000. Finally, Quantitative Investment Management LLC acquired a new stake in shares of Valeant Pharmaceuticals Intl during the fourth quarter worth about $2,327,000. 46.95% of the stock is currently owned by institutional investors and hedge funds.

Get Valeant Pharmaceuticals Intl alerts:

Several analysts have recently issued reports on the stock. TheStreet cut shares of Valeant Pharmaceuticals Intl from a “c” rating to a “d+” rating in a research report on Friday, May 25th. Jefferies Financial Group increased their price target on shares of Valeant Pharmaceuticals Intl to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, May 9th. Cantor Fitzgerald set a $25.00 price target on shares of Valeant Pharmaceuticals Intl and gave the stock a “buy” rating in a research report on Tuesday, May 8th. BTIG Research reissued a “hold” rating on shares of Valeant Pharmaceuticals Intl in a research report on Wednesday, May 9th. Finally, HC Wainwright reissued a “hold” rating and set a $16.00 price target on shares of Valeant Pharmaceuticals Intl in a research report on Monday, May 7th. Five analysts have rated the stock with a sell rating, ten have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Valeant Pharmaceuticals Intl has a consensus rating of “Hold” and a consensus target price of $20.54.

In related news, Director Schutter Richard U. De purchased 15,000 shares of the company’s stock in a transaction on Tuesday, May 15th. The shares were bought at an average cost of $21.83 per share, for a total transaction of $327,450.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 11.54% of the company’s stock.

Shares of Valeant Pharmaceuticals Intl stock opened at $23.56 on Tuesday. The company has a market capitalization of $9.38 billion, a price-to-earnings ratio of 6.15, a P/E/G ratio of 0.40 and a beta of -0.34. Valeant Pharmaceuticals Intl Inc has a 52 week low of $10.94 and a 52 week high of $27.79. The company has a debt-to-equity ratio of 5.59, a quick ratio of 0.92 and a current ratio of 1.18.

Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported $0.89 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.60 by $0.29. The company had revenue of $2 billion for the quarter, compared to analyst estimates of $1.95 billion. Valeant Pharmaceuticals Intl had a negative net margin of 10.65% and a positive return on equity of 27.87%. The firm’s revenue was down 5.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.79 earnings per share. analysts anticipate that Valeant Pharmaceuticals Intl Inc will post 3.33 EPS for the current fiscal year.

Valeant Pharmaceuticals Intl Company Profile

Valeant Pharmaceuticals International, Inc operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S.

Institutional Ownership by Quarter for Valeant Pharmaceuticals Intl (NYSE:VRX)

Leave a Reply

Your email address will not be published. Required fields are marked *